三联疗法联合利多卡因治疗慢性胃炎的疗效观察(1)
 |
| 第1页 |
参见附件(2795KB，3页)。
[摘要] 目的 探讨三联疗法联合利多卡因治疗慢性胃炎的临床疗效。方法 选取2009年2月～2010年3月来我院进行治疗的66例慢性胃炎患者，随机分为对照组和观察组，每组33例。所有患者均先使用三联疗法治疗，对照组在此基础上加用吗丁啉，观察组则加用利多卡因。观察比较两组患者的临床疗效、幽门螺杆菌(Hp)根除率及不良反应。结果 治疗后，观察组的总有效率、Hp根除率均明显高于对照组(P<0.05)；上腹痛症及嗝气症的症状积分治疗后均比治疗前显著下降(P<0.05)，且观察组的积分低于对照组(P<0.05)；两组均无严重的不良反应。结论 三联疗法联合利多卡因治疗慢性胃炎能有效减轻炎症症状，根除幽门螺杆菌，提高患者的治愈率，临床疗效显著，适宜临床推广使用。
[关键词] 利多卡因；三联疗法；慢性胃炎
[中图分类号] R573.3 [文献标识码] B [文章编号] 1673-9701(2011)33-57-02
The Efficacy of Triple Therapy Combined Lidocaine in Treatment of Chronic Gastritis
ZHAO Hongwen
Department of Gastroenterology, the Third People’s Hospital of Hangzhou, Hangzhou 310009, China
[Abstract] Objective To discuss the efficacy of triple therapy combined lidocaine in treatment of chronic gastritis. Methods Sixty-six cases with chronic gastritis were selected from February 2009 to March 2010 in our hospital, they were randomly divided into the control group and the observation group, and each group had 33 cases. All of the patients were given triple therapy firstly; The control group was given domperidone while the observation group was received triple therapy and lidocaine, and then observed the clinical curative effect, eradication of helicobacter pylori (Hp) and the occur rate of adverse reaction. Results After the treatment, the total effective rate and eradication rate of Hp in the observation group was higher than the control group (P<0.05); Symptoms scores of epigastric pain and belch gas disease of post-treatment were lower than pre-treatment (P<0.05), and the scores in the observation group were lower than the control group (P<0.05); There was no severe adverse reactions in the two groups. Conclusion Triple therapy combined lidocaine in treatment of chronic gastritis can effectively reduce the inflammation symptoms, eradicate Hp, improve clinical curing rate, and the curative effect is notable, so it is suitable for promotion in clinic.
[Key words] Lidocaine; Triple therapy; Chronic gastritis
慢性胃炎(chronic gastritis)是临床常见的消化系统疾病，发病率高，在各种胃病中位居第一，约占消化内科疾病的20%[1]，其临床上的主要病理变化为胃黏膜的非特异性慢性炎症。国内外的大量研究表明，幽门螺杆菌(helicobacter pylori，Hp)感染是慢性胃炎主要的致病因子[2]，同时证明在根除Hp后，则能较成功地治愈慢性胃炎。一般根除Hp的经典方法为标准三联疗法，即质子泵抑制剂(PPI)/铋剂、阿莫西林/咪唑类药物及克拉霉素 ......
您现在查看是摘要介绍页，详见PDF附件(2795KB，3页)。